Design of a biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD Phase 2 trials

被引：0
|
作者：
Ronco, L. [1 ]
Cadavid, D. [1 ]
Chang, A. [1 ]
Mellion, M. [1 ]
Rojas, A. [1 ]
Shen, N. [1 ]
Tawil, R. [2 ]
Tapscott, S. [3 ]
Wang, L. [3 ]
Wallace, O. [1 ]
机构：
[1] Fulcrum Therapeut, Cambridge, MA USA
[2] Univ Rochester, Med Center
[3] Univ Washington, Seattle, WA 98195 USA
来源：
NEUROMUSCULAR DISORDERS | 2019年 / 29卷
关键词：
D O I：
10.1016/j.nmd.2019.06.076
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.47
引用
收藏
页码：S54 / S55
页数：2
相关论文
共 50 条
  • [31] A Two-Stage Adaptive Design in Phase 2 Clinical Trials for Acute Treatment of Migraine
    Fan, Xiaoyin
    Assaid, Chris A.
    Ge, Yang
    Ho, Tony W. H.
    DRUG INFORMATION JOURNAL, 2011, 45 (03): : 315 - 330
  • [32] A Two-Stage Adaptive Design in Phase 2 Clinical Trials for Acute Treatment of Migraine
    Xiaoyin Frank Fan
    Chris A. Assaid
    Yang Joy Ge
    Tony W. H. Ho
    Drug information journal : DIJ / Drug Information Association, 2011, 45 : 315 - 330
  • [33] Effect of design on power calculations using MRI lesions as variable in MS phase 2 clinical trials
    Linde, AS
    Astrom, M
    Gjorstrup, P
    NEUROLOGY, 1997, 48 (03) : 45005 - 45005
  • [34] MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
    Mithoefer, Michael C.
    Feduccia, Allison A.
    Jerome, Lisa
    Mithoefer, Anne
    Wagner, Mark
    Walsh, Zach
    Hamilton, Scott
    Yazar-Klosinski, Berra
    Emerson, Amy
    Doblin, Rick
    PSYCHOPHARMACOLOGY, 2019, 236 (09) : 2735 - 2745
  • [35] Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect
    Shan, Mu
    Guo, Beibei
    Liu, Hao
    Li, Qian
    Zang, Yong
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2023, 32 (05) : 885 - 894
  • [36] RETRACTION: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
    Mithoefer, Michael C.
    Feduccia, Allison A.
    Jerome, Lisa
    Mithoefer, Anne
    Wagner, Mark
    Walsh, Zach
    Hamilton, Scott
    Yazar-Klosinski, Berra
    Emerson, Amy
    Doblin, Rick
    PSYCHOPHARMACOLOGY, 2024, 241 (11) : 2405 - 2405
  • [37] STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) - RATIONALE, DESIGN AND METHODS - 2 TRIALS THAT EVALUATE THE EFFECT OF ENALAPRIL IN PATIENTS WITH REDUCED EJECTION FRACTION
    YUSUF, S
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (03): : 315 - 322
  • [38] Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and-2)
    Wharton, Sean
    le Roux, Carel W.
    Kosiborod, Mikhail N.
    Platz, Elke
    Brueckmann, Martina
    Jastreboff, Ania M.
    Hussain, Samina Ajaz
    Pedersen, Sue D.
    Borowska, Luiza
    Unseld, Anna
    Kloer, Isabel M.
    Kaplan, Lee M.
    OBESITY, 2025, 33 (01) : 67 - 77
  • [39] Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
    Stauffer, Virginia L.
    Wang, Shufang
    Voulgaropoulos, Menelaos
    Skljarevski, Vladimir
    Kovacik, Amy
    Aurora, Sheena K.
    HEADACHE, 2019, 59 (06): : 834 - 847
  • [40] Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect
    Chu, Chenghao
    Liu, Shufang
    Rong, Alan
    PHARMACEUTICAL STATISTICS, 2020, 19 (04) : 358 - 369
12345